Saglam O - Search Results

1

Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer.

Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, Hofstatter EW, Abu-Khalaf M, Gross CP, Evans SB. Rutter CE, et al. Among authors: saglam o. Clin Breast Cancer. 2016 Feb;16(1):59-62. doi: 10.1016/j.clbc.2015.09.008. Epub 2015 Sep 21. Clin Breast Cancer. 2016. PMID: 26483315

2

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.

Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Mani NL, et al. Among authors: saglam o. Breast Cancer Res. 2016 Jul 29;18(1):78. doi: 10.1186/s13058-016-0737-x. Breast Cancer Res. 2016. PMID: 27473061 Free PMC article.

3

Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.

von Wahlde MK, Timms KM, Chagpar A, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L. von Wahlde MK, et al. Among authors: saglam o. Clin Cancer Res. 2017 Mar 1;23(5):1193-1199. doi: 10.1158/1078-0432.CCR-16-0889. Epub 2016 Sep 6. Clin Cancer Res. 2017. PMID: 27601588

4

Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.

Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Matsuo K, et al. Among authors: saglam o. J Surg Oncol. 2018 Feb;117(2):236-244. doi: 10.1002/jso.24801. Epub 2017 Aug 8. J Surg Oncol. 2018. PMID: 28787528 Free PMC article.

5

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.

Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, Saeed-Vafa D, Cubitt C, Hakam A, Magliocco AM. Saglam O, et al. Cancer Control. 2017 Jan;24(1):89-95. doi: 10.1177/107327481702400115. Cancer Control. 2017. PMID: 28178720 Free PMC article.

6

Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situ.

Saglam O, Dai F, Husain S, Zhan Y, Toruner G, Haines GK 3rd. Saglam O, et al. Hum Pathol. 2014 Jun;45(6):1269-75. doi: 10.1016/j.humpath.2014.02.007. Epub 2014 Feb 20. Hum Pathol. 2014. PMID: 24767859

7

Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.

Reid BM, Vyas S, Chen Z, Chen A, Kanetsky PA, Permuth JB, Sellers TA, Saglam O. Reid BM, et al. Among authors: saglam o. BMC Cancer. 2021 Jun 17;21(1):714. doi: 10.1186/s12885-021-08413-3. BMC Cancer. 2021. PMID: 34140011 Free PMC article.

8

AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.

Saglam O, Husain S, Toruner G. Saglam O, et al. Int J Gynecol Pathol. 2013 Sep;32(5):493-500. doi: 10.1097/PGP.0b013e31827fedef. Int J Gynecol Pathol. 2013. PMID: 23896716

9

Metastatic leiomyosarcoma presenting as bilateral, multifocal breast masses.

Vasan N, Saglam O, Killelea BK. Vasan N, et al. Among authors: saglam o. BMJ Case Rep. 2012 Dec 6;2012:bcr2012007188. doi: 10.1136/bcr-2012-007188. BMJ Case Rep. 2012. PMID: 23220834 Free PMC article.

10

Expression of hormone receptors, cell regulatory and myoepithelial cell markers in lactating breast and associated carcinomas.

Saglam O, Tavassoli FA. Saglam O, et al. Breast J. 2012 Jul-Aug;18(4):380-2. doi: 10.1111/j.1524-4741.2012.01261.x. Epub 2012 May 29. Breast J. 2012. PMID: 22640230 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters